Compare Northrop Grumman Corporation (NOC) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Northrop Grumman Corporation vs Viatris Inc — how do they compare? Northrop Grumman Corporation trades at $514.98 (market cap $74.42B), while Viatris Inc trades at $17.54 (market cap $19.79B). The key difference: Northrop Grumman Corporation is far larger — about 3.8× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.83%). Which is the better fit depends on your goals.
| NOC | VTRS | |
|---|---|---|
Market Cap | $74.42B | $19.79B |
Sector | Industrials | Health |
52-Week High | $768.02 | $17.39 |
52-Week Low | $496.02 | $8.74 |
Enterprise Value | $88.65B | $32.00B |
Dividend Yield | 1.79% | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Northrop Grumman (NOC) trades at $512.29, down 1.78% amid a bearish technical signal despite strong Q2 2026 earnings that beat estimates and a record $105 billion backlog. The stock faces margin pressures but maintains solid fundamentals with a P/E of 16.43 and ROE of 28.51%. Recent news highlights raised 2026 guidance driven by robust defense demand, though the stock's decline reflects investor concerns over cost challenges.
The outlook is mixed: bullish fundamentals and analyst consensus ($655 price target) support long-term growth, but near-term risks include execution on margin targets and technical bearishness. Investment appeal hinges on defense budget tailwinds offsetting operational headwinds.
Viatris (VTRS) trades at $17.59, up 1.74% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3B for 2025 but posted a net loss of $3.51B, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a PDUFA date set for December 2026. Cash flow from operations remains strong at $2.32B, supporting debt reduction efforts.
The outlook is mixed: analyst consensus targets $20.00 (13.7% upside), but profitability challenges and high debt levels pose risks. Investment appeal hinges on successful pipeline execution and margin recovery, while competitive and regulatory pressures in the generics market remain key watchpoints for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Northrop Grumman Corporation
Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.
Read more on NOC →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
